证券记录 · 已归档季度
TEVA
Teva Pharmaceutical Industries Limited · Healthcare · Drug Manufacturers - Specialty & Generic
21被追踪持有人
+2Δ持有人
78.93M持有股份
$1.23B报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +10.5% ·
股份流向 +27.5% ·
净新建仓位 +9.5%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 151 | +7 | 369.28M | $12.48B | +9 | −1 |
| Q1 2026 | 146 | +3 | 327.68M | $9.78B | +10 | −8 |
| Q4 2025 | 144 | -1 | 326.44M | $10.18B | +3 | −3 |
| Q3 2025 | 23 | 0 | 176.53M | $3.56B | +1 | −2 |
| Q2 2025 | 21 | 0 | 197.53M | $3.31B | n/a | n/a |
| Q1 2025 | 18 | -3 | 84.56M | $1.30B | n/a | −3 |
| Q4 2024 | 21 | -1 | 89.79M | $1.98B | n/a | −1 |
| Q3 2024 | 21 | +2 | 78.93M | $1.23B | +2 | n/a |
| Q2 2024 | 19 | n/a | 61.88M | $1.01B | n/a | n/a |
持有人 · Q3 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 11.81M | -2.6% | $212.87M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 8.79M | +3.4% | $157.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Glenview Capital ✦ | 8.46M | -7.7% | $152.38M | 3.2% | ▼ Trim | 2 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 8.11M | -7.0% | $146.20M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 5 | Viking Global Investors ✦ | 7.57M | 新增 | $136.37M | 0.5% | New | 1 | SEC ↗ |
| 6 | Arrowstreet Capital ✦ | 14.90M | +156.7% | $72.24M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 3.65M | -37.9% | $65.85M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 3.62M | +72.2% | $65.27M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 3.47M | +96.1% | $62.50M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 10 | Marshall Wace ✦ | 2.74M | -34.2% | $49.46M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 11 | Norges Bank ✦ (被动) | 1.52M | +41.2% | $27.32M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Duquesne Family Office ✦ | 1.43M | 新增 | $25.73M | 0.9% | New | 1 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 825.43K | +224.8% | $14.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 715.15K | +419.7% | $12.89M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 517.71K | -60.8% | $9.33M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Greenlight Capital (DME Capital) ✦ | 324.85K | 0.0% | $5.85M | 0.2% | Held | 2 | SEC ↗ ×2 |
| 17 | Wellington Management ✦ | 182.10K | -2.2% | $3.28M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 18 | GAMCO Investors ✦ | 129.70K | -3.4% | $2.34M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | ARK Investment Management ✦ | 123.86K | -26.9% | $2.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 23.22K | +5.2% | $418,460 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 17.58K | +8.9% | $316,738 | 0.0% | ▲ Add | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Viking Global Investors | $136.37M | 0.5% |
| Duquesne Family Office | $25.73M | 0.9% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 646 持有人, 666.61M 股份, $16.70B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 18
Savage Brian
Officer · 2.52K 股 · $98,841
Sep 18
MIGNONE ROBERTO
Director · 367.60K 股 · $14.36M
Sep 18
Savage Brian
Officer · 4.50K 股 · $174,221
Sep 18
Savage Brian
Officer · 314 股 · $12,153
Aug 21
Weiss Amir
Officer · 2.50K 股 · $94,077
Aug 21
Satchi-Fainaro Ronit
Director · 415 股 · $15,459
Aug 21
Weiss Amir
Officer · 6.95K 股 · $261,224
Aug 17
Lippman Evan
Officer · 18.60K 股 · $680,291
Aug 05
Zaks Tal Zvi
Director · 17 股 · $593
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2024 ·
方法论 ·
通过API获取此数据